Recent advances in cancer outcomes in HIV-positive smokers

[version 1; peer review: 2 approved]

Sabina Ranjit, Santosh Kumar

Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Avenue, Room 456, Memphis, TN, 38163, USA

First published: 11 Jun 2018, 7(F1000 Faculty Rev):718
https://doi.org/10.12688/f1000research.12068.1
Latest published: 11 Jun 2018, 7(F1000 Faculty Rev):718
https://doi.org/10.12688/f1000research.12068.1

Abstract
HIV-infected smokers are at relatively higher risk of cancer than HIV-infected non-smokers. HIV weakens the immune system and renders infected individuals more vulnerable to the carcinogenic effects of smoking. HIV-infected smokers suffer more aggressive forms of cancers than do non-smokers because of the cumulative effects of the virus and cigarette smoke carcinogens. The major types of cancer observed in HIV-infected smokers are lung, head and neck, esophageal, anal, and cervical cancers. In this review, we will discuss the recent advances in cancer outcomes, primarily in terms of cancer incidence, prevalence, and progression in HIV patients who are smokers.

Keywords
HIV, tobacco smoking, cancer

Open Peer Review

Approval Status ✔ ✔

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>version 1</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>11 Jun 2018</td>
<td>✔</td>
<td>✔</td>
</tr>
</tbody>
</table>

Faculty Reviews are review articles written by the prestigious Members of Faculty Opinions. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. Elizabeth Chiao, Baylor College of Medicine, Houston, USA
2. Matthias Egger, University of Bern, Bern, Switzerland

Any comments on the article can be found at the end of the article.
Corresponding author: Santosh Kumar (ksantosh@uthsc.edu)

Author roles: Ranjit S: Conceptualization, Writing – Original Draft Preparation; Kumar S: Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The authors acknowledge financial support from the National Institutes of Health (grants AA022063 and DA042374). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Ranjit S and Kumar S. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Ranjit S and Kumar S. Recent advances in cancer outcomes in HIV-positive smokers [version 1; peer review: 2 approved] F1000Research 2018, 7(F1000 Faculty Rev):718 https://doi.org/10.12688/f1000research.12068.1

First published: 11 Jun 2018, 7(F1000 Faculty Rev):718 https://doi.org/10.12688/f1000research.12068.1
Introduction

About 1.2 million people are currently suffering from HIV/AIDS in the US. The Joint United Nations Programme on HIV/AIDS (UNAIDS) reveals that deaths resulting from HIV infection dropped by 45% between 2005 and 2015 (UNAIDS 2015 report). The decrease in HIV-related deaths can be attributed to the advancements in combination antiretroviral therapy (cART). cART has elongated the life spans of people living with HIV/AIDS (PLWHAs). However, the burden of cancer (especially non-Hodgkin’s lymphoma, Kaposi’s sarcoma, anal cancer, and lung cancer) has substantially increased in those patients (by about 50%)\(^1\). Cancer-related deaths in PLWHAs have increased by 8% within the span of a decade from 2000 to 2010\(^2\).

HIV weakens the immune system of infected patients and makes them vulnerable to cancer-associated viruses such as human herpesvirus 8 (HHV8), Epstein–Barr virus (EBV), and human papillomavirus (HPV)\(^3\). These viruses cause Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and cervical cancer, respectively. As the prevalences of these cancers are specifically higher in patients with HIV, they are referred to as AIDS-defining cancers (ADCs)\(^4\). Patients with HIV are also susceptible to other non-ADCs (NADCs) such as Hodgkin’s lymphoma and anal, skin, liver, kidney, lung, mouth, throat, and testicular cancers\(^5\). According to the recent study by the Division of Cancer Epidemiology and Genetics, National Cancer Institute, USA (2014), the number of ADC cases was observed to have decreased over the period from 1996 to 2010 while the number of NADCs such as anal, liver, and prostate cancer was found to have increased\(^6\). The report published on European HIV cohorts revealed similar trends of ADCs and NADCs in patients with HIV over the period of 2001 to 2012\(^7\). The report further emphasizes that the decline in ADCs is due to the use of cART, which effectively suppressed viral replication and reversed immunosuppression in patients with HIV. The increase in NADCs could be due to the higher life expectancy of PLWHAs receiving cART and to other risk factors for cancer such as high smoking rate and heavy alcohol drinking. A study of Spanish HIV-infected patients in 2017 reported hepatocellular carcinoma (20.5%), lung (18.7%), head and neck (11.9%), and anal (10.5%) as the most common types of NADCs\(^8\). In the African HIV population, which comprises about 50% of global HIV patients, NADCs were observed to be increased by 33.8% from 2002 to 2014\(^9\). In this review, we will discuss the recent advances in cancers, primarily the extent of cancer incidence, prevalence, and progression among HIV patients as a consequence of smoking.

Prevalence of smoking in HIV-infected patients

In a cross-sectional survey conducted on 419,945 patients with HIV in the US in 2015, 42.4% were current smokers, 20.3% were former smokers, and 37.3% were non-smokers\(^10\). According to the study, the prevalence of smoking in patients with HIV (42.4%) was more than two times higher than the uninfected US adult population (20.6%). A similar trend of smoking prevalence was observed in a study surveying HIV-infected patients in New York in 2016, which found the association of smoking with poor health outcomes among PLWHAs\(^11\). A study conducted in Ontario, Canada, in 2008 reported that 39.3% of the patients with HIV were smokers, which declined by 1.6% by 2014. However, the rate of smoking remained higher in the HIV population than in the general population\(^12\). About 33% of patients with HIV in a South African study were also found to be smokers\(^13\). Furthermore, the prevalence of smoking is much higher among male HIV patients who have sex with men (MSM) than it is among uninfected men\(^14\). Jin et al. performed a meta-analysis of 102 studies that included only Chinese PLWHAs, and the authors reported the prevalence of smoking to be 41.1% among the study population\(^15\).

Table 1 summarizes the prevalence of smoking among patients with HIV in different countries (most of the patients are from the US) from 2014 to 2017\(^16\)–\(^21\), showing that smoking is highly prevalent in HIV-infected populations.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Date of publication</th>
<th>Location</th>
<th>Patients with HIV, number</th>
<th>HIV-infected smokers, percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mdodo et al.(^11)</td>
<td>2015</td>
<td>US</td>
<td>419,945</td>
<td>42.4</td>
</tr>
<tr>
<td>Hile et al.(^12)</td>
<td>2016</td>
<td>US</td>
<td>14,713</td>
<td>40</td>
</tr>
<tr>
<td>Bekele et al.(^13)</td>
<td>2017</td>
<td>Canada</td>
<td>4,473</td>
<td>39.3</td>
</tr>
<tr>
<td>Akhtar-Khaleel et al.(^16)</td>
<td>2016</td>
<td>US</td>
<td>6,577</td>
<td>36.9</td>
</tr>
<tr>
<td>Pacek et al.(^19)</td>
<td>2014</td>
<td>US</td>
<td>358</td>
<td>75</td>
</tr>
<tr>
<td>Pollack et al.(^21)</td>
<td>2017</td>
<td>Vietnam</td>
<td>636</td>
<td>36.3</td>
</tr>
<tr>
<td>Murrison et al.(^14)</td>
<td>2016</td>
<td>South Africa</td>
<td>146</td>
<td>33</td>
</tr>
<tr>
<td>Brath et al.(^20)</td>
<td>2016</td>
<td>Austria and Germany</td>
<td>447</td>
<td>49.4</td>
</tr>
</tbody>
</table>

It can be noted that the literatures within the table have performed analysis independent of the information from other literatures within the table. Papers with reference number 11, 12, 13, 14, 16, 19, 20, 21, and 22 used original information. However, in the case of meta-analysis in some literatures (papers with reference 18 and 23), they have information from literatures present outside the table.
Cancer risk in HIV-infected smokers

Several reports suggest that smoking is a risk factor for cancer development in PLWHA. A study by Helleberg et al. on 3,503 HIV-infected patients and 12,979 uninfected individuals in Denmark concluded that the risk of smoking-related cancers is much higher in HIV-infected smokers compared with both the general population and HIV-infected non-smokers. The study also found that about 23% of the cancers in the HIV-infected population were related to smoking. The authors classified the smoking-related cancers as lung cancer, head and neck cancer (HNC), esophageal cancer, and bladder cancer on the basis of the International Classifications of Diseases, 10th version (ICD-10). According to the study, the incidence rate ratios (IRRs) of smoking-related cancer associated with current smoking were 21.35 in patients with HIV and 4.12 within the general population. Similarly, another study performed by the same researchers on HIV-infected patients in Europe and North America reported that the mortality rate ratio for HIV-infected smokers versus non-smokers due to NADC was 3.13, which also indicates smoking as an important risk factor for cancers in patients with HIV.

Smoking-induced cancers in HIV-infected smokers

Shepherd et al. conducted a study in HIV cohorts across 33 European countries, which indicated the significant association of smoking with infection-unrelated malignancies (IURMs) (IRR = 1.75 when compared with never-smokers) rather than infection-related malignancies (IRMs). The study classified virus-induced cancers caused by EBV (Hodgkin's/non-Hodgkin's lymphoma), hepatitis B and C viruses (liver cancer), HHV8 (Kaposi's sarcoma), and HPV (cervical, anal, and stomach cancer) as IRMs. IURMs included lung, prostate, colorectal, and breast cancer. However, several reports in the literature suggest that smoking is also associated with some definitely virally induced cancers such as HNC and cervical and liver cancer and some potentially virally induced cancers such as esophageal cancer.

In Table 2, we have summarized the incidence rate (IR) of the smoking-associated cancers among HIV-infected patients in the last four years (2014–2017). In general, the rates of incidence of lung cancer, anal cancer, HNC, cervical cancer, and esophageal cancer were 66–175, 76–146.8, 24–80, 21–506, and 12–21 per 100,000 person-years (PY), respectively. In the following sections, we will briefly discuss the recent findings on risk, prevalence, and progression of the most common cancers in HIV-positive smokers.

Lung cancer

The IRR for lung cancer is about 1.7–2 in HIV-infected smokers compared with the general population. Hessol et al. reported higher incidence of lung cancer in HIV-infected smokers (IR/100,000 PY = 119) than in uninfected smokers (IR/100,000 PY = 45). According to Makinson et al., HIV-infected smokers tend to suffer from lung cancer at a relatively younger age than the uninfected population. Reddy et al. used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-US model to estimate the cumulative lung cancer mortality rate in 40-year-old men who were HIV-positive smokers. They estimated that the lung cancer mortality rate for current smokers in the study group was about 18 times higher than for individuals who had never smoked and about 3.8 times higher.

Table 2. Incidence of cancers in HIV-infected patients.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Date of publication</th>
<th>Location</th>
<th>Cancer type</th>
<th>Incidence rate, cancers per 100,000 person-years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helleberg et al.</td>
<td>2014</td>
<td>Denmark</td>
<td>Lung</td>
<td>91</td>
</tr>
<tr>
<td>Hessol et al.</td>
<td>2015</td>
<td>US</td>
<td>Lung</td>
<td>119</td>
</tr>
<tr>
<td>Marcus et al.</td>
<td>2017</td>
<td>US</td>
<td>Lung</td>
<td>66</td>
</tr>
<tr>
<td>Park et al.</td>
<td>2016</td>
<td>US</td>
<td>Lung</td>
<td>175</td>
</tr>
<tr>
<td>Helleberg et al.</td>
<td>2014</td>
<td>Denmark</td>
<td>Esophageal</td>
<td>21</td>
</tr>
<tr>
<td>Park et al.</td>
<td>2016</td>
<td>US</td>
<td>Esophageal</td>
<td>12</td>
</tr>
<tr>
<td>Park et al.</td>
<td>2016</td>
<td>US</td>
<td>Non-HIV-related oral cavity</td>
<td>24</td>
</tr>
<tr>
<td>Helleberg et al.</td>
<td>2014</td>
<td>Denmark</td>
<td>Head and neck</td>
<td>80</td>
</tr>
<tr>
<td>Chiao et al.</td>
<td>2014</td>
<td>US</td>
<td>Anal</td>
<td>134.3–146.8</td>
</tr>
<tr>
<td>Park et al.</td>
<td>2016</td>
<td>US</td>
<td>Anal</td>
<td>76</td>
</tr>
<tr>
<td>Ekanem and Parkin</td>
<td>2016</td>
<td>Nigeria</td>
<td>Cervix</td>
<td>21</td>
</tr>
<tr>
<td>Helleberg et al.</td>
<td>2014</td>
<td>Denmark</td>
<td>Cervix</td>
<td>25</td>
</tr>
<tr>
<td>Rohner et al.</td>
<td>2017</td>
<td>South Africa</td>
<td>Cervix</td>
<td>506</td>
</tr>
</tbody>
</table>

It can be noted that the literatures within the table have performed analysis independent of the information from other literatures within the table. Papers with reference number 24, 26, 31, 22, 32, and 34 used original information. However, the paper with reference 23 has performed meta-analysis based on information from literatures present outside the table.
than those who quit smoking at the age of 40 years. However, the lung cancer burden in patients with HIV has declined (~2.8%) in the past few years in the US and this could be due to the decrease in the smoking prevalence over the period. The analysis of lung histology in American patients with HIV revealed the most common types of lung cancer observed in American PLWHAs to be adenocarcinoma followed by squamous cell carcinoma and other non-small cell carcinoma. A similar study conducted on Chinese cohorts by Cheng et al. suggested that the majority (85%) of the HIV patients with lung cancer had non-small cell carcinoma and that nearly half of the study groups were at stage IIIb and IV of lung cancer.

The study by Marcus et al. in 2017 showed that the lung cancer rate ratio decreased from 1.4 to 1.2 when they calculated the lung cancer risk after adjustment for pneumonia. Furthermore, the study indicated HIV-mediated immunosuppression as a lung cancer risk factor in patients with HIV. Hence, factors other than smoking such as HIV-induced immunosuppression and history of lung diseases such as AIDS-related pneumonia also contribute as cumulative risk factors for lung cancer in PLWHAs.

Head and neck cancer

HNC includes the cancers of larynx, oropharynx, oral cavity, and nasal cavity. The IR of HNC in HIV-infected smokers in the US ranges from 1.3 to 1.8 per 100,000 PY. A study by Faggons et al. on African patients with HIV suggested that 43% of the patients with HNC were tobacco smokers. The study also pointed out that cancers of the larynx, oropharynx, and oral cavity were the most common among HIV-positive smokers. Another study performed by D’Souza et al. among American HIV-HNC patients also reported about four times greater prevalence of smoking among HIV-positive patients with HNC compared with HIV-negative individuals for HNC. Furthermore, in the same study group, they observed that HIV patients suffered from HNC at a younger age (median age = 50 years) compared with the uninfected population (median age = 62 years).

The most common type of HNCs observed was cancer of the oral cavity followed by oropharyngeal cancer and larynx cancer. Interestingly, the authors also observed a higher prevalence of HNCs in HIV patients who were currently on ART (77%) compared with those who were not (23%). Since HPV was detected in about 30% of the HIV patients with HNC (primarily in oropharyngeal cancers), the study implicated HPV infection, in addition to tobacco smoking, as a risk factor for HNC in patients with HIV.

Esophageal cancer

The study conducted by McCormack et al. in six sub-Saharan African countries showed a high association of tobacco smoking with the risk of esophageal cancer (odds ratio [OR] = 2.6–8.0). The study also confirmed that most of the patients in their study were HIV-positive. Another study in Denmark also suggested that PLWHAs are at higher risk of esophageal cancer (IR/100,000 PY = 8.0) compared with uninfected individuals. Several studies have reported the association of smoking with esophageal cancer risk in HIV-infected patients. Moses et al. reported an OR of about 2.02 for smokers versus non-smokers for esophageal cancer in HIV-infected patients in Malawi. Another study conducted in Zambia by Kayamba et al. also reported that cigarette smoking, independent of HIV infection, conferred high risk of esophageal cancer in HIV-infected patients (OR = 3.5). Furthermore, the study reported a higher prevalence of esophageal squamous cell carcinoma at the middle section (60.4%) of the esophagus, followed by the distal (26.4%) and proximal (10.6%) sections.

Anal cancer

Most studies published in recent years report that HPV is a major risk factor for the prevalence of anal cancer in patients with HIV, especially among MSM. Some studies also indicate smoking as an indirect risk for anal cancer, as it triggers HPV replication. A study performed in HIV-infected women by Gaisa et al. reported that the risk of anal cancer doubled in HIV-infected smokers. Another study from Wieland et al. suggested that smoking is a risk factor for anal cancer in HIV-infected men, especially MSM. Higher HPV DNA loads, higher prevalence of high/low-grade intraepithelial lesions, and greater incidence of anal dysplasia were observed in HIV-infected MSM who were smokers compared with those who were non-smokers. Although the anal cancer rate has risen over the last decade, the cancer survival rate has also increased by 62–67% after chemoradiotherapy. However, the recurrence rates for anal cancer are still high, ranging from 30% to 60% in HIV patients compared with uninfected populations, and this is probably due to lower tolerance of chemoradiotherapy.

Cervical cancer

Cervical cancer is an ADC with higher risk and prevalence among HIV-1-infected women compared with uninfected women. The IR of cervical cancer is about three times higher in HIV-infected women than in HIV-uninfected women. Although HPV infection is the major cause of cervical cancer, several studies in the past have implicated cigarette smoking as a cofactor for cervical cancer in both HIV-infected and uninfected women. Moreover, most of the recent studies have emphasized HPV infection, immunosuppression by HIV, age, abortion, and vaginal abnormalities as major risk factors for cervical cancer in HIV-infected women. Only a few recent reports associate smoking with cervical cancer risk in HIV-infected women. A study of HIV-infected sub-Saharan African women by Rohner et al. reported that the IR of cervical cancer in HIV-infected women is 506/100,000 PY, which is higher than in European populations.

Conclusions

Smoking is highly prevalent among HIV-infected patients compared with the general population. Therefore, HIV-infected individuals are at higher risk of tobacco-related health complications, particularly cancers. Several studies have shown a strong association of smoking with cancer incidence in patients with HIV. The recent studies have reported the predominant prevalence of lung, head and neck, esophageal, anal, and cervical cancers in HIV-infected smokers. Smoking cessation intervention could be a crucial preventive measure to reduce the incidence of cancers in PLWHAs. In the cases of HIV-infected patients already suffering
from cancer, smoking cessation may help to decelerate the progression or reduce the severity of the disease. Awareness, counseling, and campaigns regarding the hazards of smoking are crucial to motivate and assist HIV-infected smokers to quit smoking. In addition to motivational efforts, medical treatments to alleviate tobacco addiction, such as the use of nicotine alternatives like nicotine patches, gums, inhalers, lozenges, and nasal sprays, should be encouraged. Alternatively, medications such as bupropion and varenicline may also help reduce the incidence of cigarette smoking. Finally, cancer prevalence and severity are more prominent among untreated PLWHAs rather than those receiving cART. Therefore, early initiation of cART and early diagnostic screenings for cancer in PLWHAs are important strategies to reduce cancer risks in these patients.

Competing interests
The authors declare that they have no competing interests.

Grant information
The authors acknowledge financial support from the National Institutes of Health (grants AA022063 and DA042374).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments
The authors acknowledge Benjamin J. Patterson for critically reading the manuscript.

References


Open Peer Review

Current Peer Review Status: ✅ ✅

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of Faculty Opinions. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

1. Matthias Egger
   Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
   Competing Interests: No competing interests were disclosed.

2. Elizabeth Chiao
   Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA
   Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com